Search results for "PLATELET ACTIVATION"

showing 10 items of 121 documents

Comprehensive platelet phenotyping supports the role of platelets in the pathogenesis of acute venous thromboembolism - results from clinical observa…

2020

Background: The pathogenesis of arterial and venous thrombosis is in large part interlaced. How much platelet phenotype relates to acute venous thromboembolism (VTE) independent of the underlying cardiovascular profile is presently poorly investigated.Methods: Platelet count and mean platelet volume (MPV), platelet aggregation in whole blood and platelet rich plasma (PRP), platelet-dependent thrombin generation (TG) and platelet surface activation markers were measured under standardized conditions. Machine learning was applied to identify the most relevant characteristics associated with VTE from a large array (N = 58) of clinical and plateletrelated variables.Findings: VTE cases (N = 159)…

Male0301 basic medicinePlatelet Aggregationlcsh:MedicineDETERMINANTSGastroenterologyMachine LearningPathogenesisACTIVATION0302 clinical medicineRisk FactorsPlateletWhole bloodlcsh:R5-920AspirinOUTCOMESThrombinVenous ThromboembolismGeneral MedicineMiddle AgedThrombosisVenous thrombosis030220 oncology & carcinogenesisAcute DiseaseFemaleDisease Susceptibilitylcsh:Medicine (General)Research Papermedicine.drugBlood Plateletsmedicine.medical_specialtyPlatelet Function TestsGeneral Biochemistry Genetics and Molecular BiologyImmunophenotyping03 medical and health sciencesACUTE PULMONARY-EMBOLISMRISK-FACTORInternal medicinemedicineHumansMean platelet volumeMETAANALYSISAgedPlatelet Countbusiness.industrylcsh:RPlatelet Activationmedicine.diseasePREVENTIONASPIRINTHROMBOSIS030104 developmental biologyPlatelet-rich plasmaVOLUMEbusinessBiomarkersEBioMedicine
researchProduct

Mean Platelet Volume and Arterial Stiffness - Clinical Relationship and Common Genetic Variability

2017

AbstractVessel wall stiffening is an important clinical parameter, but it is unknown whether platelets, key elements in the pathogenesis of arterial thrombosis, are associated with arterial stiffness. The present studies sought to determine whether mean platelet volume (MPV), a potential marker of platelet activation, is linked to vascular elasticity as assessed by the augmentation index (AIx), in 15,010 individuals from the population-based Gutenberg Health Study. Multivariable analysis showed that MPV in both males (β 0.776; 95thCI [0.250;1.16]; p = 0.0024) and females (β 0.881[0.328;1.43]; p = 0.0018) is strongly associated with AIx. Individuals with MPV and AIx above the sex-specific me…

Male0301 basic medicinemedicine.medical_specialtyPopulationKaplan-Meier Estimate030204 cardiovascular system & hematologyPolymorphism Single NucleotideArticle03 medical and health sciencesSex FactorsVascular Stiffness0302 clinical medicineGUTENBERG HEALTHDEFICIENTINFLAMMATIONRisk FactorsInternal medicinemedicineHumansPlateletPlatelet activationMean platelet volumeeducationMETAANALYSISeducation.field_of_studyMultidisciplinaryHYPERTENSIONbusiness.industryProportional hazards modelHazard ratioGenetic VariationCROSS-SECTIONAL RELATIONSmedicine.diseaseThrombosisElasticityREACTIVITY030104 developmental biologyISCHEMIC-STROKEATHEROSCLEROSISCardiovascular DiseasesArterial stiffnessCardiologyFemalebusinessMean Platelet VolumeVASCULAR FUNCTIONBiomarkers
researchProduct

Vascular imaging of solid tumors in rats with a radioactive arsenic-labeled antibody that binds exposed phosphatidylserine.

2008

Abstract Purpose: We recently reported that anionic phospholipids, principally phosphatidylserine, become exposed on the external surface of vascular endothelial cells in tumors, probably in response to oxidative stresses present in the tumor microenvironment. In the present study, we tested the hypothesis that a chimeric monoclonal antibody that binds phosphatidylserine could be labeled with radioactive arsenic isotopes and used for molecular imaging of solid tumors in rats. Experimental Design: Bavituximab was labeled with 74As (β+, T1/2 17.8 days) or 77As (β−, T1/2 1.6 days) using a novel procedure. The radionuclides of arsenic were selected because their long half-lives are consistent w…

MaleCancer ResearchPathologymedicine.medical_specialtyBiodistributionBavituximabmedicine.drug_classPhosphatidylserinesMonoclonal antibodyArticleArsenicchemistry.chemical_compoundIn vivomedicineTumor Cells CulturedAnimalsTissue DistributionPlatelet activationRadioisotopesTumor microenvironmentbiologyNeovascularization PathologicAntibodies MonoclonalProstatic NeoplasmsPhosphatidylserineMolecular biologyXenograft Model Antitumor AssaysRatsOncologychemistryRadioimmunodetectionPositron-Emission Tomographybiology.proteinEndothelium VascularAntibodymedicine.drugClinical cancer research : an official journal of the American Association for Cancer Research
researchProduct

Enhanced lipid peroxidation and platelet activation as potential contributors to increased cardiovascular risk in the low-HDL phenotype

2013

Background Low high‐density lipoprotein ( HDL ) levels are major predictors of cardiovascular ( CV ) events, even in patients on statin treatment with low‐density lipoprotein ( LDL ) at target. In animal models HDL s protect LDL from oxidation and blunt platelet activation. Our study aimed to examine whether HDL levels are related to in vivo oxidative stress and platelet activation, as determinants of atherothrombosis. Methods and Results Urinary 8‐iso‐PGF 2α and 11‐dehydro‐TXB 2 , in vivo markers of oxidative stress and platelet activation, respectively, were measured in 65 coronary heart disease (CHD) normocholesterolemic patients with HDL ≤35 mg/ dL , and in 47 CHD patients with HDL &gt…

MaleSettore MED/09 - Medicina InternaCoronary DiseaseDinoprostmedicine.disease_causeLipid peroxidationchemistry.chemical_compoundFenofibrateHDL cholesterolRisk FactorsCoronary Heart Diseaseoxidative stressMyocardial infarctionOriginal ResearchHypolipidemic AgentsplateletHypoalphalipoproteinemiasFenofibrateMiddle AgedAged; Arachidonic Acids; Case-Control Studies; Cholesterol HDL; Coronary Disease; Cross-Sectional Studies; Dinoprost; Exercise; Exercise Therapy; Female; Fenofibrate; Humans; Hypoalphalipoproteinemias; Hypolipidemic Agents; Lipid Peroxidation; Male; Middle Aged; Oxidative Stress; Phenotype; Platelet Activation; Risk Factors; Sedentary Lifestyle; Thromboxane B2; Cardiology and Cardiovascular MedicineExercise TherapyCholesterolPhenotypeSedentary LifestyleFemalelipids (amino acids peptides and proteins)exercise HDL cholesterol oxidative stress plateletCardiology and Cardiovascular Medicinemedicine.drugmedicine.medical_specialtyHDLArachidonic AcidsDiabetes mellitusInternal medicinemedicineHumansPlatelet activationExerciseAgedCreatininebusiness.industryCholesterol HDLCase-control studyPlatelet Activationmedicine.diseaseThromboxane B2Cross-Sectional StudiesEndocrinologychemistryCase-Control StudiesLipid PeroxidationSedentary BehaviorbusinessOxidative stressLipoproteinEuropean Heart Journal
researchProduct

Determinants of enhanced thromboxane biosynthesis in renal transplantation

2001

Determinants of enhanced thromboxane biosynthesis in renal transplantation.BackgroundDespite great improvement in patient and graft survival, the long-term morbidity and mortality in renal transplant recipients (RTRs) are still significant, with a high incidence of cardiovascular disease-related deaths.MethodsWe investigated thromboxane (TXA2) biosynthesis and endothelial and coagulative activation in 65 patients who received a renal transplant.ResultsThe rate of TXA2 biosynthesis (urinary 11-dehydro-TXB2 excretion largely reflects platelet TXA2 production in vivo) was significantly (P < 0.0001) higher in RTRs than in healthy subjects. Plasma von Willebrand factor (vWF) and thrombin-antithr…

MaleSettore MED/09 - Medicina InternaThromboxanegraft survivalThromboxanevon Willebrand factorImmunosuppressive AgentThromboxane A2chemistry.chemical_compoundReference ValuesRenal Dialysicardiovascular diseaseReference ValuePlateletPostoperative PeriodKidney transplantationKidneyimmunosuppressionnephrotoxicityThromboxanesMiddle AgedCholesterolmedicine.anatomical_structureNephrologyCyclosporineFemaleCardiovascular disease; Graft survival; Immunosuppression; Kidney transplantation; Nephrotoxicity; Von Willebrand factor; Adult; Antithrombin III; Cardiovascular Diseases; Cholesterol; Cyclosporine; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged; Peptide Hydrolases; Postoperative Period; Reference Values; Renal Dialysis; Thromboxanes; von Willebrand Factor; Kidney Transplantation; NephrologyImmunosuppressive AgentsHumancirculatory and respiratory physiologyAdultmedicine.medical_specialtyAntithrombin IIIUrologykidney transplantationFollow-Up StudieEndothelial activationRenal DialysismedicineHumansPlatelet activationcardiovascular disease; cardiovascular diseases; graft survival; immunosuppression; kidney transplantation; nephrotoxicity; von willebrand factorbusiness.industrymedicine.diseasecardiovascular diseasesTransplantationPeptide HydrolasechemistryImmunologybusinessFollow-Up StudiesPeptide HydrolasesKidney International
researchProduct

Does the NO/sGC/cGMP/PKG pathway play a stimulatory role in platelets?

2012

Nitric oxide (NO) stimulates cGMP synthesis by activating its intracellular receptor, soluble guanylyl cyclase (sGC). It is a currently prevailing concept that No and cGMP inhibits platelet function. However, the data supporting the inhibitory role of NO/sGC/cGMP in platelets have been obtained either in vitro or using whole body gene deletion that affects vessel wall function. Here we have generated mice with sGC gene deleted only in megakaryocytes and platelets. Using the megakaryocyte- and platelet-specific sGC-deficient mice, we identify a stimulatory role of sGC in platelet activation and in thrombosis in vivo. Deletion of sGC in platelets abolished cGMP production induced by either NO…

Maleinorganic chemicalsbusiness.industryImmunologyReceptors Cytoplasmic and NuclearCell BiologyHematologyPlatelet ActivationPlatelets and ThrombopoiesisBiochemistryCell biologyCyclic gmpGuanylate Cyclasecardiovascular systemAnimalsMedicineFemaleheterocyclic compoundsPlateletbusinessSoluble guanylyl cyclaseBlood
researchProduct

Usefulness of Clopidogrel Loading in Patients Who Underwent Transcatheter Aortic Valve Implantation (from the BRAVO-3 Randomized Trial)

2018

P2Y12-inhibitor initiation with clopidogrel using a loading dose (LD) versus no LD (NLD) provides more rapid inhibition of platelet activation and reduced risk of ischemic events after coronary stenting. Whether a similar beneficial effect is achieved in the setting of transcatheter aortic valve implantation (TAVI) is unknown. We evaluate the effects of preprocedural clopidogrel LD versus no NLD on 48-hour and 30-day clinical outcomes after TAVI. In the BRAVO-3 trial, 802 patients with severe aortic stenosis who underwent transfemoral TAVI were randomized to intraprocedural anticoagulation with bivalirudin or unfractionated heparin. Administration of clopidogrel LD was left to the discretio…

Malemedicine.medical_specialtyTime Factors030204 cardiovascular system & hematologyRisk AssessmentLoading doseTranscatheter Aortic Valve Replacement03 medical and health sciencesPostoperative Complications0302 clinical medicineRisk FactorsThromboembolismInternal medicinePreoperative CaremedicineHumansBivalirudinProspective Studies030212 general & internal medicinePlatelet activationMyocardial infarction610 Medicine &amp; healthProspective cohort studyStrokeAged 80 and overDose-Response Relationship Drugbusiness.industryIncidenceAortic Valve Stenosismedicine.diseaseClopidogrelClopidogrelEuropeStenosisNorth AmericaPurinergic P2Y Receptor AntagonistsCardiologyFemaleCardiology and Cardiovascular MedicinebusinessFollow-Up Studiesmedicine.drugThe American Journal of Cardiology
researchProduct

CAPD + hemoperfusion once a week in the management of children with end-stage renal disease

1983

With hemoperfusion there is a sharp decline in the solute concentration of the blood compartment, but immediately after HP the concentration of these substances rises to the original level (post-Hp rebound). It may be inferred that the result would be better and the rebound phenomenon less marked if hemoperfusion could be combined with a continuous dialysis system such as CAPD. The study was performed in 3 children of our CAPD programm. All patients were dialysed with 5 daily exchange each of one liter. The patients underwent at 2-hours hemoperfusion with a charcoal column (Gambro Adsorba 150 c) once a week. The data obtained with this form of treatment are indicative for a: significant in…

Malemedicine.medical_specialtymedicine.medical_treatment030232 urology & nephrologyBiomedical EngineeringUrologyMedicine (miscellaneous)Bioengineering030204 cardiovascular system & hematologyEnd stage renal diseasePeritoneal dialysisBiomaterials03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePeritoneal Dialysis Continuous AmbulatoryHumansMedicinePlatelet activationChildIntensive care medicineDialysisCreatininebusiness.industryLiterGeneral MedicineHemoperfusionUric AcidHemoperfusionchemistryCreatinineKidney Failure ChronicUric acidFemalebusinessPeritoneal Dialysis
researchProduct

Modification of human platelet adhesion on biomaterial surfaces by protein preadsorption under static and flow conditions.

2004

Biomaterial-induced thrombosis remains one of the main complications of vascular implant devices. Preadsorbed proteins on the biomaterial/blood interface will modify the adhesion and activation of platelets (PTLs) during the initial contact-phase. Our results clearly show that PTL-adherence on biomaterials is influenced not only by protein preadsorption, but also by flow conditions. The covalent coating of TCPS and glass by phosphorylcholine (PC) induces a significant decrease of PTL adhesion but leads to a slight, but nevertheless significant activation of PTL, which was detected by the induction of P-selectin expression using FACS analysis. Methodologically, the visualization of PTL adhes…

Materials scienceBiomedical EngineeringBiophysicschemistry.chemical_elementBioengineeringBiocompatible MaterialsCalciumIn Vitro TechniquesBiomaterialsBlood cellPlatelet AdhesivenessIn vivoMaterials TestingmedicineHumansPlateletPhosphorylcholineBiomaterialThrombosisAdhesionBlood ProteinsFlow CytometryPlatelet ActivationBiomechanical PhenomenaBlood Vessel ProsthesisP-Selectinmedicine.anatomical_structurechemistryembryonic structuresImmunologyHemorheologyBiophysicsAdsorptionProtein adsorptionJournal of materials science. Materials in medicine
researchProduct

Dynamics of CXC group chemokine platelet factor 4 (PF4) plasma levels in non-small cell lung cancer (NSCLC)

2012

CXC chemokines display pleiotropic effects participating not only in inflammation, but regulating angiogenesis and metastatic spread in cancer. Platelet factor 4 (PF4) is a 70-amino acid protein belonging to the CXC chemokine family. PF4 is also known as CXCL4. This chemokine is released from alpha-granules of activated platelets and binds with high affinity to heparin-like molecules promoting coagulation. Megakaryocytes respond to the presence of tumors by increasing their number in the bone marrow accompanied by increase in the number of platelets in circulation, causing changes in chemokine balance.

Medicine(all)ChemokinebiologyBiochemistry Genetics and Molecular Biology(all)Angiogenesisbusiness.industrylcsh:Rlcsh:MedicineCancerInflammationGeneral Medicinemedicine.diseaseGeneral Biochemistry Genetics and Molecular Biologymedicine.anatomical_structurePoster PresentationImmunologymedicinebiology.proteinPlateletPlatelet activationBone marrowmedicine.symptombusinessPlatelet factor 4Journal of Translational Medicine
researchProduct